BIOMAT Database Logo BIOMAT Database Logo

Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy. 2005

Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
State Reference Center for Sanitary Dermatology and Leprosy, Clinical Hospital, Faculty of Medicine, Federal University of Uberlândia, Minas Gerai, Brazil. imbgoulart@ufu.br

UI MeSH Term Description Entries
D007917 Leprostatic Agents Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. Antileprotic Agents,Leprostatics,Agents, Antileprotic,Agents, Leprostatic
D008297 Male Males
D001938 Brazil A country located on the eastern coast of South America, located between Colombia and Peru, that borders the Atlantic Ocean. It is bordered on the north by Venezuela, Guyana, Suriname, and French Guiana, on the south by Uruguay, and on the west by Argentina. The capital is Brasilia.
D002991 Clofazimine A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619) B-663,G-30,320,Lamprene,N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine,B 663,B663,G 30,320,G30,320
D003622 Dapsone A sulfone active against a wide range of bacteria but mainly employed for its actions against MYCOBACTERIUM LEPRAE. Its mechanism of action is probably similar to that of the SULFONAMIDES which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with PYRIMETHAMINE in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) Diaminodiphenylsulfone,Sulfonyldianiline,4,4'-Diaminophenyl Sulfone,Avlosulfone,DADPS,Dapsoderm-X,Dapson-Fatol,Diaphenylsulfone,Disulone,Sulfona,4,4' Diaminophenyl Sulfone,Sulfone, 4,4'-Diaminophenyl
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000741 Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. Anemia, Hypoplastic,Aplastic Anaemia,Aplastic Anemia,Anaemia, Aplastic,Aplastic Anaemias,Aplastic Anemias,Hypoplastic Anemia,Hypoplastic Anemias
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin

Related Publications

Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Dapsone alone compared with dapsone plus rifampicin in short-term therapy of lepromatous leprosy.
December 1977, Leprosy review,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae.
May 1972, The American journal of tropical medicine and hygiene,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
January 1984, Indian journal of leprosy,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Spaced clofazimine therapy of lepromatous leprosy.
May 1976, The American journal of tropical medicine and hygiene,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Case Report: Borderline Lepromatous Leprosy Therapy Complicated by Type 1 Leprosy Reaction and Adverse Reactions with Dapsone and Clofazimine.
March 2024, The American journal of tropical medicine and hygiene,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Clofazimine therapy for lepromatous leprosy: a historical perspective.
January 1999, International journal of dermatology,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Intermittent rifampicin therapy in lepromatous leprosy.
January 1980, Leprosy in India,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Low dose dapsone therapy in lepromatous leprosy.
June 1975, Leprosy review,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
January 1984, Indian journal of leprosy,
Isabela M B Goulart, and Ana Cláudia S Reis, and Tatiana M N De Rezende, and Aércio S Borges, and Marcelo S Ferreira, and Sérgio A Nishioka
The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy.
December 1986, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!